PHP
TVTX icon

Parkman Healthcare Partners’s Travere Therapeutics TVTX Stock Holding History

Parkman Healthcare Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-86,297
Closed -$3.3M – 114
2025
Q4 		$3.3M Sell
86,297
-253,467
-75% -$8.24M 0.31% 78
2025
Q3 		$8.12M Sell
339,764
-487,296
-59% -$9.16M 0.85% 42
2025
Q2 		$12.2M Sell
827,060
-127,011
-13% -$2.11M 1.41% 24
2025
Q1 		$17.1M Sell
954,071
-163,721
-15% -$3.32M 2.03% 15
2024
Q4 		$19.5M Buy
1,117,792
+31,725
+3% +$561K 2.59% 12
2024
Q3 		$15.2M Buy
1,086,067
+116,175
+12% +$1.21M 1.94% 16
2024
Q2 		$7.97M Buy
969,892
+1,472
+0.2% +$9.91K 1.07% 38
2024
Q1 		$7.47M Sell
968,420
-50,392
-5% -$425K 0.92% 40
2023
Q4 		$9.16M Buy
1,018,812
+441,318
+76% +$3.21M 1.29% 25
2023
Q3 		$5.16M Buy
577,494
+431,171
+295% +$6.08M 0.95% 35
2023
Q2 		$2.25M Buy
146,323
+4,436
+3% +$80.7K 0.39% 70
2023
Q1 		$3.19M Buy
141,887
+119,052
+521% +$2.53M 0.69% 46
2022
Q4 		$480K Sell
22,835
-3,730
-14% -$79K 0.13% 77
2022
Q3 		$655K Buy
26,565
+315
+1% +$8.14K 0.19% 81
2022
Q2 		$636K Buy
+26,250
New +$660K 0.23% 65

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parkman Healthcare Partners's TVTX Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 86,297 shares — an estimated $3.3M sold.

Parkman Healthcare Partners first reported a position in TVTX in Q2 2022 and held it in 15 quarters. The position peaked at $19.5M in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 86,297 Travere Therapeutics shares in Q1 2026, an estimated $3.3M.
  • Parkman Healthcare Partners first reported a position in Travere Therapeutics in Q2 2022 and held it in 15 quarters.
  • Parkman Healthcare Partners's Travere Therapeutics position peaked at $19.5M in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.